Developer docs
API playgroundTry for free, no card

Search company profiles

Monarch Medical Technologies

Full company profile

uuid0000dng

Namestring
Monarch Medical Technologies
Legal namestring
Monarch Medical Technologies LLC
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Monarch Medical Technologies develops and markets the EndoTool Glucose Management System, an FDA-cleared Class II medical device that delivers patient-specific insulin dosing recommendations for inpatient glycemic management. Founded in 2003 by Dr. Patrick Burgess, the company built its core technology around a proprietary adaptive algorithm that incorporates 11+ patient-specific clinical factors—including renal function, weight, age, sex, and real-time glucose values—and continuously recalculates dosing recommendations. A distinctive feature is the Estimated Residual Extracellular Insulin (EREI) calculation, which models residual circulating insulin to prevent overdosing, particularly in patients with renal impairment. The product portfolio comprises EndoTool IV for intravenous insulin therapy, EndoTool SubQ for subcutaneous insulin delivery, and the newly-cleared EndoTool IV Cloud, a cloud-based architecture launched in 2026.

The company generates revenue through direct enterprise sales to U.S. hospital systems under multi-year subscription contracts, with pricing scaled to organization size and modules. The go-to-motion is enterprise field sales targeting hospital leadership, pharmacy, quality/safety, and clinical decision-makers, supported by 15-minute product demonstrations, on-site and remote training, EHR integration services, and ongoing customer success management. Customers include Trinity Health, Corewell Health, Atrium Health Wake Forest Baptist, UPMC, Sharp HealthCare, Beacon Health System, Northside Hospital, CaroMont Health, Cone Health, and Temple Health, with the platform deployed across 100+ U.S. health systems including 8 of the top 10. The product maintains deep HL7-based integrations with Epic, Cerner/Oracle Health, and Meditech, and is supported by over 50 peer-reviewed clinical studies documenting outcomes such as severe hypoglycemia rates as low as 0.005%, $12M in savings for a single health system, and 84% decreases in hypoglycemic events.

In September 2025, Monarch was acquired by Glooko, a California-based digital health company that had raised a $100M Series F in October 2024, integrating EndoTool into a comprehensive hospital-to-home diabetes management platform. The company now operates as "Monarch Medical Technologies, a Glooko Company" and holds SOC 2 Type II, ISO 13485, and FDA 21 CFR Part 11 compliance certifications. Headquartered in Charlotte, North Carolina with 11-50 employees, Monarch continues to sell and support EndoTool alongside Glooko's outpatient diabetes management portfolio, with the May 2026 EndoTool IV Cloud FDA 510(k) clearance marking the most recent expansion of the product platform.

Short descriptiontext

Monarch Medical Technologies provides EndoTool, an FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, serving 100+ U.S. hospital systems with adaptive algorithms and EREI calculations. Acquired by Glooko in September 2025 to form an integrated hospital-to-home diabetes platform.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin dosing software, glycemic management system, inpatient diabetes management, clinical decision support, patient-specific dosing
Industry2 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAKADAA
Diabetes (General)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Clinical Decision Support Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Software Subscription / License
TypeSubscription Recurring
Description

Enterprise software licensing model for hospital systems. Pricing varies based on hospital size, number of locations, and specific product modules (EndoTool IV and/or SubQ). Includes implementation, training, and ongoing support as part of the contract.

monarchmedtech.com
2Professional Services (Implementation & Training)
TypeProfessional Services
Description

Implementation services include pre-launch preparation, discovery and scoping, technical build-out, EHR integration testing, and clinical validation. Training includes on-site, remote, and eLearning modules. Ongoing support and customer success management included.

monarchmedtech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Custom Enterprise Pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

The cost of EndoTool varies depending on your specific needs and healthcare setting. We provide tailored pricing models to best fit your organization's requirements and budget.

monarchmedtech.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1EndoTool
Description

FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, including EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin delivery. The platform uses patented patient-specific algorithms to provide real-time insulin dosing recommendations for hospitalized patients.

monarchmedtech.com
Core offering1 text field

Monarch Medical Technologies develops and sells EndoTool, an FDA-cleared Class II medical device software that delivers patient-specific insulin dosing recommendations for hospitalized patients. The platform supports both intravenous (EndoTool IV) and subcutaneous (EndoTool SubQ) insulin delivery using a proprietary adaptive algorithm, and integrates with major hospital EHR systems. A cloud-based version (EndoTool IV Cloud) received FDA 510(k) clearance in 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Severe hypoglycemia rate reduced to 0.005% (Sharp HealthCare)
+5 more records
Product overview1 text field

Monarch Medical Technologies, a Glooko company, offers the EndoTool® Glucose Management System - a family of FDA-cleared patient-specific insulin dosing solutions for hospital inpatient glycemic care. The portfolio consists of two core products: EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin dosing, both using a proprietary patient-specific algorithm that adapts to individual patient physiology. The company also launched EndoTool IV Cloud in 2026, a cloud-based architecture enabling more scalable deployment. All products are backed by clinical evidence and designed to reduce hypoglycemia risk while standardizing insulin dosing protocols across healthcare systems.

Product and service1 record
1EndoTool IV
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1mylife Diabetes Care
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-14
Description

Glooko announced an expanded partnership with mylife Diabetes Care, positioning Glooko as the primary data management platform for mylife's connected diabetes products.

mddionline.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Glooko acquired Monarch Medical Technologies in September 2025 to expand its connected diabetes care platform into inpatient glycemic management. The acquisition integrates EndoTool with Glooko's outpatient diabetes management solutions to create a comprehensive hospital-to-home diabetes management platform. Following the $100M Series F financing in October 2024, Glooko positioned EndoTool as a core component of its integrated diabetes ecosystem.

Strategic tierCoreTypeTechnology or Integration
Description

EndoTool integrates with Epic EHR systems, enabling clinicians to launch EndoTool and receive dosing recommendations directly within the Epic workflow.

4Cerner (Oracle Health)
Strategic tierCoreTypeTechnology or Integration
Description

EndoTool integrates with Cerner (now Oracle Health) EHR systems, allowing seamless data exchange and workflow optimization.

monarchmedtech.com
Strategic tierCoreTypeTechnology or Integration
Description

EndoTool integrates with Meditech EHR platforms for hospitals using Meditech's electronic medical record systems.

6Oracle Health
Strategic tierCoreTypeTechnology or Integration
Description

Following Cerner's acquisition by Oracle, EndoTool supports integration with Oracle Health platforms.

monarchmedtech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Glytec is the closest direct competitor to Monarch's EndoTool, offering the eGlycemic Management System for hospital inpatient insulin dosing. Both companies compete head-to-head in selling FDA-cleared, EHR-integrated glycemic decision support software to U.S. hospital systems and health networks.

TypeBroad incumbent
Description

Roche Diabetes Care is a large incumbent offering insulin pumps, CGM systems, and digital diabetes management tools. While its core focus is outpatient and home-use devices, it operates adjacent to Monarch's hospital dosing space and competes for diabetes management budget within integrated delivery networks.

TypeBroad incumbent
Description

Medtronic Diabetes is a leader in insulin pumps and automated insulin delivery systems aimed primarily at outpatient diabetes management. It is comparable to Monarch as part of the broader diabetes technology ecosystem targeting the same endocrinologist and health system stakeholders.

TypeBroad incumbent
Description

Dexcom is a leading continuous glucose monitor (CGM) manufacturer whose devices increasingly feed real-time glucose data into inpatient dosing workflows. Its data is complementary to but increasingly overlapping with Monarch's dosing decisions, making it a relevant ecosystem peer.

TypeBroad incumbent
Description

Abbott Diabetes Care manufactures FreeStyle Libre CGM systems used in hospital settings alongside inpatient insulin protocols. It competes for the same hospital glucose management budget and increasingly integrates its CGM data into dosing and analytics workflows comparable to Monarch's.

TypeBroad incumbent
Description

Insulet manufactures the Omnipod tubeless insulin pump, primarily for outpatient diabetes management. It is a broad diabetes technology incumbent whose automated insulin delivery offerings compete for the broader hospital and health system diabetes management wallet.

TypeBroad incumbent
Description

Tandem Diabetes Care produces insulin pumps and automated insulin delivery systems including the t:slim X2 with Control-IQ. It targets the same endocrinologist decision-makers and increasingly the inpatient dosing workflow as Monarch's EndoTool.

TypeOthers
Description

Novo Nordisk is a leading insulin and GLP-1 manufacturer that supplies the drugs whose dosing Monarch's software optimizes. It is a thematically related player rather than a direct competitor but influences hospital insulin protocols and partnerships.

TypeOthers
Description

Eli Lilly manufactures insulins and GLP-1 therapies whose dosing and titration Monarch's software manages. As a major diabetes pharmaceutical incumbent, it shapes hospital protocols and is a natural adjacent ecosystem participant rather than direct competitor.

TypeOthers
Description

Glooko is the parent company of Monarch following the September 2025 acquisition and operates the outpatient diabetes management and remote patient monitoring platform that Monarch's EndoTool is now integrated with. It is the platform partner and customer-facing commercial vehicle for Monarch's hospital-to-home expansion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Monarch Medical Technologies

Clinical Decision Support Softwaremonarchmedtech.com

Monarch Medical Technologies provides EndoTool, an FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, serving 100+ U.S. hospital systems with adaptive algorithms and EREI calculations. Acquired by Glooko in September 2025 to form an integrated hospital-to-home diabetes platform.

What Monarch Medical Technologies does

Monarch Medical Technologies develops and markets the EndoTool Glucose Management System, an FDA-cleared Class II medical device that delivers patient-specific insulin dosing recommendations for inpatient glycemic management. Founded in 2003 by Dr. Patrick Burgess, the company built its core technology around a proprietary adaptive algorithm that incorporates 11+ patient-specific clinical factors—including renal function, weight, age, sex, and real-time glucose values—and continuously recalculates dosing recommendations. A distinctive feature is the Estimated Residual Extracellular Insulin (EREI) calculation, which models residual circulating insulin to prevent overdosing, particularly in patients with renal impairment. The product portfolio comprises EndoTool IV for intravenous insulin therapy, EndoTool SubQ for subcutaneous insulin delivery, and the newly-cleared EndoTool IV Cloud, a cloud-based architecture launched in 2026.

The company generates revenue through direct enterprise sales to U.S. hospital systems under multi-year subscription contracts, with pricing scaled to organization size and modules. The go-to-motion is enterprise field sales targeting hospital leadership, pharmacy, quality/safety, and clinical decision-makers, supported by 15-minute product demonstrations, on-site and remote training, EHR integration services, and ongoing customer success management. Customers include Trinity Health, Corewell Health, Atrium Health Wake Forest Baptist, UPMC, Sharp HealthCare, Beacon Health System, Northside Hospital, CaroMont Health, Cone Health, and Temple Health, with the platform deployed across 100+ U.S. health systems including 8 of the top 10. The product maintains deep HL7-based integrations with Epic, Cerner/Oracle Health, and Meditech, and is supported by over 50 peer-reviewed clinical studies documenting outcomes such as severe hypoglycemia rates as low as 0.005%, $12M in savings for a single health system, and 84% decreases in hypoglycemic events.

In September 2025, Monarch was acquired by Glooko, a California-based digital health company that had raised a $100M Series F in October 2024, integrating EndoTool into a comprehensive hospital-to-home diabetes management platform. The company now operates as "Monarch Medical Technologies, a Glooko Company" and holds SOC 2 Type II, ISO 13485, and FDA 21 CFR Part 11 compliance certifications. Headquartered in Charlotte, North Carolina with 11-50 employees, Monarch continues to sell and support EndoTool alongside Glooko's outpatient diabetes management portfolio, with the May 2026 EndoTool IV Cloud FDA 510(k) clearance marking the most recent expansion of the product platform.

Monarch Medical Technologies firmographics

Firmographics
Name
Monarch Medical Technologies
Legal name
Monarch Medical Technologies LLC
Website
https://monarchmedtech.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
11–50 employees
Short description
Monarch Medical Technologies provides EndoTool, an FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, serving 100+ U.S. hospital systems with adaptive algorithms and EREI calculations. Acquired by Glooko in September 2025 to form an integrated hospital-to-home diabetes platform.
Ownership category
akta.pro rank

Monarch Medical Technologies industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAKADAA
Diabetes (General)

Keywords

  • Insulin dosing software
  • Glycemic management system
  • Inpatient diabetes management
  • Clinical decision support
  • Patient-specific dosing

Where Monarch Medical Technologies is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Monarch Medical Technologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Subscription / License: Enterprise software licensing model for hospital systems. Pricing varies based on hospital size, number of locations, and specific product modules (EndoTool IV and/or SubQ). Includes implementation, training, and ongoing support as part of the contract.
  2. Professional Services (Implementation & Training): Implementation services include pre-launch preparation, discovery and scoping, technical build-out, EHR integration testing, and clinical validation. Training includes on-site, remote, and eLearning modules. Ongoing support and customer success management included.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCustom Enterprise Pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Monarch Medical Technologies product offering

Product offering

Core offering

Monarch Medical Technologies develops and sells EndoTool, an FDA-cleared Class II medical device software that delivers patient-specific insulin dosing recommendations for hospitalized patients. The platform supports both intravenous (EndoTool IV) and subcutaneous (EndoTool SubQ) insulin delivery using a proprietary adaptive algorithm, and integrates with major hospital EHR systems. A cloud-based version (EndoTool IV Cloud) received FDA 510(k) clearance in 2026.

Product overview

Monarch Medical Technologies, a Glooko company, offers the EndoTool® Glucose Management System - a family of FDA-cleared patient-specific insulin dosing solutions for hospital inpatient glycemic care. The portfolio consists of two core products: EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin dosing, both using a proprietary patient-specific algorithm that adapts to individual patient physiology. The company also launched EndoTool IV Cloud in 2026, a cloud-based architecture enabling more scalable deployment. All products are backed by clinical evidence and designed to reduce hypoglycemia risk while standardizing insulin dosing protocols across healthcare systems.

Differentiator

Problem solved

Functional benefit

Brands

  • EndoTool: FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, including EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin delivery. The platform uses patented patient-specific algorithms to provide real-time insulin dosing recommendations for hospitalized patients.

Products and services

  • EndoTool IV

Quantifiable outcome

  • Severe hypoglycemia rate reduced to 0.005% (Sharp HealthCare)
  • +5 more outcomes

Companies that use Monarch Medical Technologies

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Monarch Medical Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature4 records

Monarch Medical Technologies partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • mylife Diabetes CareminorGTM or Marketing Partner · 14 May 2026Glooko announced an expanded partnership with mylife Diabetes Care, positioning Glooko as the primary data management platform for mylife's connected diabetes products.
  • GlookocoreStrategic or Co-development Partner · 1 September 2025Glooko acquired Monarch Medical Technologies in September 2025 to expand its connected diabetes care platform into inpatient glycemic management. The acquisition integrates EndoTool with Glooko's outpatient diabetes management solutions to create a comprehensive hospital-to-home diabetes management platform. Following the $100M Series F financing in October 2024, Glooko positioned EndoTool as a core component of its integrated diabetes ecosystem.
  • EpiccoreTechnology or IntegrationEndoTool integrates with Epic EHR systems, enabling clinicians to launch EndoTool and receive dosing recommendations directly within the Epic workflow.
  • Cerner (Oracle Health)coreTechnology or IntegrationEndoTool integrates with Cerner (now Oracle Health) EHR systems, allowing seamless data exchange and workflow optimization.
  • MeditechcoreTechnology or IntegrationEndoTool integrates with Meditech EHR platforms for hospitals using Meditech's electronic medical record systems.
  • Oracle HealthcoreTechnology or IntegrationFollowing Cerner's acquisition by Oracle, EndoTool supports integration with Oracle Health platforms.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Monarch Medical Technologies competitors and assessment

Company assessment

Direct peers

  • Glytec: Glytec is the closest direct competitor to Monarch's EndoTool, offering the eGlycemic Management System for hospital inpatient insulin dosing. Both companies compete head-to-head in selling FDA-cleared, EHR-integrated glycemic decision support software to U.S. hospital systems and health networks.

Broad incumbents

  • Roche Diabetes Care: Roche Diabetes Care is a large incumbent offering insulin pumps, CGM systems, and digital diabetes management tools. While its core focus is outpatient and home-use devices, it operates adjacent to Monarch's hospital dosing space and competes for diabetes management budget within integrated delivery networks.
  • Medtronic Diabetes: Medtronic Diabetes is a leader in insulin pumps and automated insulin delivery systems aimed primarily at outpatient diabetes management. It is comparable to Monarch as part of the broader diabetes technology ecosystem targeting the same endocrinologist and health system stakeholders.
  • Dexcom: Dexcom is a leading continuous glucose monitor (CGM) manufacturer whose devices increasingly feed real-time glucose data into inpatient dosing workflows. Its data is complementary to but increasingly overlapping with Monarch's dosing decisions, making it a relevant ecosystem peer.
  • Abbott Diabetes Care: Abbott Diabetes Care manufactures FreeStyle Libre CGM systems used in hospital settings alongside inpatient insulin protocols. It competes for the same hospital glucose management budget and increasingly integrates its CGM data into dosing and analytics workflows comparable to Monarch's.
  • Insulet Corporation: Insulet manufactures the Omnipod tubeless insulin pump, primarily for outpatient diabetes management. It is a broad diabetes technology incumbent whose automated insulin delivery offerings compete for the broader hospital and health system diabetes management wallet.
  • Tandem Diabetes Care: Tandem Diabetes Care produces insulin pumps and automated insulin delivery systems including the t:slim X2 with Control-IQ. It targets the same endocrinologist decision-makers and increasingly the inpatient dosing workflow as Monarch's EndoTool.

Others

  • Novo Nordisk: Novo Nordisk is a leading insulin and GLP-1 manufacturer that supplies the drugs whose dosing Monarch's software optimizes. It is a thematically related player rather than a direct competitor but influences hospital insulin protocols and partnerships.
  • Eli Lilly: Eli Lilly manufactures insulins and GLP-1 therapies whose dosing and titration Monarch's software manages. As a major diabetes pharmaceutical incumbent, it shapes hospital protocols and is a natural adjacent ecosystem participant rather than direct competitor.
  • Glooko: Glooko is the parent company of Monarch following the September 2025 acquisition and operates the outpatient diabetes management and remote patient monitoring platform that Monarch's EndoTool is now integrated with. It is the platform partner and customer-facing commercial vehicle for Monarch's hospital-to-home expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Monarch Medical Technologies social profiles

Digital presence

Monarch Medical Technologies compliance and trust

Trust signal

Compliance3 records

Monarch Medical Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Monarch Medical Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Monarch Medical Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Monarch Medical Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Monarch Medical Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monarch Medical Technologies

What does Monarch Medical Technologies do?

Monarch Medical Technologies develops and sells EndoTool, an FDA-cleared Class II medical device software that delivers patient-specific insulin dosing recommendations for hospitalized patients. The platform supports both intravenous (EndoTool IV) and subcutaneous (EndoTool SubQ) insulin delivery using a proprietary adaptive algorithm, and integrates with major hospital EHR systems. A cloud-based version (EndoTool IV Cloud) received FDA 510(k) clearance in 2026.

Is Monarch Medical Technologies a public or private company?

Monarch Medical Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Monarch Medical Technologies founded?

Monarch Medical Technologies was founded in 2003. It employs 11 to 50 people.

Where is Monarch Medical Technologies based?

Monarch Medical Technologies is headquartered in Charlotte, United States, in the North America region.

How does Monarch Medical Technologies make money?

Two revenue lines are on record. Software Subscription / License is the primary driver. The others are professional Services (Implementation & Training).

Who are Monarch Medical Technologies's main competitors?

Glytec is listed as a direct peer. Broad incumbents are Roche Diabetes Care, Medtronic Diabetes, Dexcom, Abbott Diabetes Care, Insulet Corporation and Tandem Diabetes Care. Others are Novo Nordisk, Eli Lilly and Glooko.

Does Monarch Medical Technologies have an API?

No public API is recorded for Monarch Medical Technologies.

What industry is Monarch Medical Technologies in?

Monarch Medical Technologies's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAKADAA, Diabetes (General). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogNew EndoTool IV Data Presented at AACE Show Virtual Elimination of Severe Hypoglycemia Across 19 HospitalsGlooko presented EndoTool IV data at the AACE Annual Meeting, showing a 98% reduction in severe hypoglycemia across 19 hospitals. The three-year analysis of 17,838 patients found severe hypoglycemia incidence dropped to 0.005% versus 0.23% under paper protocols, with low severe hyperglycemia at 0.17%.Healthcare IT TodayGlooko Announces Acquisition of Monarch Medical Technologies, Maker of EndoTool Glucose Management System, to Expand Connected Diabetes Care OfferingsGlooko acquired Monarch Medical Technologies, maker of the EndoTool inpatient insulin dosing system, to expand its connected diabetes care into hospitals. The deal integrates EndoTool with Glooko's outpatient platform, aiming to support patients across the full care continuum. Terms were not disclosed.Medical BuyerGlooko acquires Monarch Medical TechnologiesGlooko acquired Monarch Medical Technologies, adding its EndoTool inpatient insulin dosing platform to its outpatient diabetes management suite. The acquisition expands Glooko's connected care across the full continuum, with both products continuing to operate separately in the near term. Glooko plans to integrate them on a single platform long-term.Business Wire BlogGlooko Announces Acquisition of Monarch Medical Technologies, Maker of EndoTool® Glucose Management System, to Expand Connected Diabetes Care OfferingsGlooko, Inc. announced the acquisition of Monarch Medical Technologies, the developer of the EndoTool® Glucose Management System, to expand its diabetes digital health platform into the inpatient glycemic management space. The EndoTool platform is an FDA-cleared software solution using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Following its $100 million Series F financing in October 2024, Glooko plans to integrate both offerings on a single platform to create a comprehensive hospital-to-home diabetes management solution.GlookoGlooko Announces Acquisition of Monarch Medical Technologies, Maker of EndoTool® Glucose Management System, to Expand Connected Diabetes Care OfferingsGlooko, Inc. has acquired Monarch Medical Technologies, the developer of the EndoTool Glucose Management System, to expand its diabetes digital health platform into inpatient glycemic management. The acquisition creates a comprehensive inpatient-to-outpatient diabetes management solution, enabling Glooko to support patients across the full continuum of care from hospital to home. The deal follows Glooko's $100 million Series F financing round in October 2024, during which the company indicated plans to accelerate growth through selective acquisitions.YahooGlooko Announces Acquisition of Monarch Medical Technologies, Maker of EndoTool® Glucose Management System, to Expand Connected Diabetes Care OfferingsGlooko announced the acquisition of Monarch Medical Technologies, a developer of the EndoTool Glucose Management System, aiming to expand its connected diabetes care platform into hospitals. This move strengthens Glooko's inpatient glycemic management capabilities and integrates inpatient and outpatient care solutions. The acquisition supports Glooko’s goal to improve diabetes management outcomes across the full care continuum.Silicon Valley JournalsMonarch Medical Technologies Received New Investment From Semler ScientificSemler Scientific announced an investment of up to $5.0 million in Monarch Medical Technologies through the purchase of a senior secured convertible promissory note. This strategic move complements Semler's existing glycemic management offerings, specifically its Insulin Insights program, by integrating with Monarch's FDA-cleared EndoTool system used in over 100 U.S. health systems.BioSpaceSemler Announces Investment in Monarch Medical TechnologiesSemler Scientific, Inc. announced an investment of up to $5.0 million in Monarch Medical Technologies through the purchase of a senior secured convertible promissory note. The investment supports Monarch's EndoTool® Glucose Management System, which complements Semler's existing Insulin Insights™ application for diabetes care. This move expands Semler's network in the diabetes management space by adding a second company focused on glycemic control.PR NewswireSemler Announces Investment in Monarch Medical TechnologiesSemler Scientific, Inc. announced an investment of up to $5.0 million in Monarch Medical Technologies, LLC, through a senior secured convertible promissory note. This investment secures Semler's interest in Monarch's assets and enhances its portfolio in the diabetes management sector, which also includes its own Insulin Insights™ application. The company aims to address nursing shortages and improve glucose management in hospitals with Monarch's technology.